Clinical outcomes of volume of disease on patients receiving enzalutamide abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Clinical outcomes of volume of disease on patients receiving enzalutamide abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and Enza have shown similar overall survival (OS) ben...

Full description

Bibliographic Details
Main Authors:	Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Talal El Zarif, Matthew P. Davidsohn, Heather McClure, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Praful Ravi, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-03-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231156147

Similar Items

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
by: Pier Vitale Nuzzo, et al.
Published: (2023-02-01)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
by: Takuya Tsujino, et al.
Published: (2023-10-01)

Abiraterone is associated with higher odds of cardiac complications compared to enzalutamide
by: E.B. Cone, et al.
Published: (2020-07-01)

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
by: Onur Baser, et al.
Published: (2024-04-01)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Published: (2023-06-01)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
by: Ying Zhang, et al.
Published: (2022-12-01)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
by: G. Gravis, et al.
Published: (2020-07-01)

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning
by: Anouk C. de Jong, et al.
Published: (2023-04-01)

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.
by: Yash B Shah, et al.
Published: (2022-01-01)

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer
by: Yash B. Shah, et al.
Published: (2022-01-01)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
by: Phoebe A. Tsao, et al.
Published: (2023-08-01)

Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide.
by: Per Johansson, et al.
Published: (2023-01-01)

Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide
by: Per Johansson, et al.
Published: (2023-01-01)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
by: Mike Fang, et al.
Published: (2017-01-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
by: Ondřej Fiala, et al.
Published: (2024-01-01)

Management of locally advanced prostate cancer before the era of abiraterone/enzalutamide: A case study from India
by: Sudhir Rawal
Published: (2015-12-01)

The short-term efficacy and safety of abiraterone acetate with prednisone in metastatic castration-resistant prostate cancer patients in vghtc
by: Chi-Feng Hung, et al.
Published: (2015-06-01)

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
by: Min Liu, et al.
Published: (2023-05-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
by: Dawid Sigorski, et al.
Published: (2023-04-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer
by: Yu-Chao Ni, et al.
Published: (2022-01-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
by: Kouji Izumi, et al.
Published: (2022-07-01)

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE
by: Daniele Santini, et al.
Published: (2021-02-01)

Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis
by: Giovanni Farinea, et al.
Published: (2024-08-01)

Enzalutamide Prolonged the Duration of Drug Use in Comparison to Abiraterone Acetate and Cabazitaxel after Upfront Docetaxel: A Large Japanese Database Study
by: Katsuya Yamaguchi, et al.
Published: (2024-07-01)

Study protocol for a comparative effectiveness evaluation of abiraterone acetate against enzalutamide: a longitudinal study based on Swedish administrative registers
by: Sophie Langenskiöld, et al.
Published: (2021-10-01)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
by: Takashi Kawahara, et al.
Published: (2023-03-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-01-01)

Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Xin Wang, et al.
Published: (2020-11-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Comparison of outcomes for patients with metastatic castrate resistant prostate cancer treated by urologists or medical oncologists with first line abiraterone acetate or enzalutamide: A population-based study
by: D.T.S. Woon, et al.
Published: (2020-07-01)

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial
by: Mariola B. Rak, et al.
Published: (2023-03-01)

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
by: Klara Kvorning Ternov, et al.
Published: (2019-09-01)